No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
No Data
Nova Mentis Announces Change of Directors
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Nova Mentis to Enter MRNA AI Diagnostics Business
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial